Marc Sanson
- Genetics top 0.02%
- Glioma Diagnosis and Treatment 224
- Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism 37
- MicroRNA in disease regulation 28
- Neurology top 0.2%
- Neurofibromatosis and Schwannoma Cases 34
- Pulmonary and Respiratory Medicine top 0.5%
- Brain Metastases and Treatment 50
-
- Meningioma and schwannoma management 55
-
- Chromatin Remodeling and Cancer 25
- Epigenetics and DNA Methylation 24
- Co-authors
- Khê Hoang‐XuanAhmed IdbaïhKarima MokhtariJean‐Yves DelattreYannick MarieBlandine BoisselierFlorence Laigle–DonadeyAlain Carpentier
- Cited by
- GeneticsCancer ResearchNeurology
- Journals
- Neuro-Oncology (41 papers)Journal of Neuro-Oncology (36 papers)Journal of Clinical Oncology (28 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Marc Sanson
306 papers receiving 13.9k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Genetics 8.6k
- Cancer Research 3.8k
- Neurology 2.5k
- Pulmonary and Respiratory Medicine 3.1k
- Radiology, Nuclear Medicine and Imaging 1.8k
Countries citing papers authored by Marc Sanson
This map shows the geographic impact of Marc Sanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Sanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Sanson more than expected).
Fields of papers citing papers by Marc Sanson
This network shows the impact of papers produced by Marc Sanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Sanson. The network helps show where Marc Sanson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marc Sanson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 49 | |
| 5 | 2022 | 6 | |
| 6 | Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Studybreakdown → | 2021 | 171 |
| 7 | 2020 | 4 | |
| 8 | 2018 | 42 | |
| 9 | 2015 | 81 | |
| 10 | 2015 | 41 | |
| 11 | 2014 | 178 | |
| 12 | 2014 | 24 | |
| 13 | 2012 | 92 | |
| 14 | 2012 | 24 | |
| 15 | 2011 | 83 | |
| 16 | 2010 | 402 | |
| 17 | 2010 | 304 | |
| 18 | Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomasbreakdown → | 2009 | 773 |
| 19 | Vers une classification moléculaire des gliomes | 2005 | 6 |
| 20 | Biologie et thérapie génique des gliomes. | 1996 | 0 |
About Marc Sanson
Marc Sanson is a scholar working on Genetics, Cancer Research and Neurology, having authored 319 papers that have together received 14.1k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (224 papers), Meningioma and schwannoma management (55 papers), Brain Metastases and Treatment (50 papers), Cancer, Hypoxia, and Metabolism (37 papers), Neurofibromatosis and Schwannoma Cases (34 papers), MicroRNA in disease regulation (28 papers), Chromatin Remodeling and Cancer (25 papers) and Epigenetics and DNA Methylation (24 papers). The work is most often cited by research in Genetics (8.6k citations), Cancer Research (3.8k citations) and Neurology (2.5k citations). Marc Sanson has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Khê Hoang‐Xuan, Ahmed Idbaïh, Karima Mokhtari, Jean‐Yves Delattre, Yannick Marie, Blandine Boisselier, Florence Laigle–Donadey, Alain Carpentier, Martin J. van den Bent and François Ducray. Their work appears in journals such as Neuro-Oncology, Journal of Neuro-Oncology, Journal of Clinical Oncology, Neurology and Annals of Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.